Hanmi Science (008930) - Total Liabilities
Based on the latest financial reports, Hanmi Science (008930) has total liabilities worth ₩529.85 Billion KRW (≈ $359.07 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hanmi Science - Total Liabilities Trend (2000–2025)
This chart illustrates how Hanmi Science's total liabilities have evolved over time, based on quarterly financial data. See 008930 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Hanmi Science Competitors by Total Liabilities
The table below lists competitors of Hanmi Science ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China Merchants Property Operation & Service Co Ltd
SHE:001914
|
China | CN¥8.87 Billion |
|
KEDE Numerical Control Co Ltd
SHG:688305
|
China | CN¥392.19 Million |
|
Svitzer Group A/S
CO:SVITZR
|
Denmark | Dkr5.62 Billion |
|
Embracer Group AB (publ)
ST:EMBRAC-B
|
Sweden | Skr7.27 Billion |
|
Allied Properties Real Estate Investment Trust
TO:AP-UN
|
Canada | CA$4.64 Billion |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $138.49 Million |
|
Sally Beauty Holdings Inc
NYSE:SBH
|
USA | $2.03 Billion |
|
Indiamart Intermesh Limited
NSE:INDIAMART
|
India | Rs22.24 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Hanmi Science's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Hanmi Science stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hanmi Science's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hanmi Science (2000–2025)
The table below shows the annual total liabilities of Hanmi Science from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩529.85 Billion ≈ $359.07 Million |
+3.82% |
| 2024-12-31 | ₩510.38 Billion ≈ $345.87 Million |
+16.34% |
| 2023-12-31 | ₩438.70 Billion ≈ $297.30 Million |
+13.96% |
| 2022-12-31 | ₩384.94 Billion ≈ $260.87 Million |
+48.28% |
| 2021-12-31 | ₩259.60 Billion ≈ $175.93 Million |
-1.85% |
| 2020-12-31 | ₩264.49 Billion ≈ $179.24 Million |
-0.25% |
| 2019-12-31 | ₩265.15 Billion ≈ $179.69 Million |
+0.64% |
| 2018-12-31 | ₩263.45 Billion ≈ $178.54 Million |
-3.72% |
| 2017-12-31 | ₩273.63 Billion ≈ $185.44 Million |
-14.94% |
| 2016-12-31 | ₩321.68 Billion ≈ $218.00 Million |
-7.50% |
| 2015-12-31 | ₩347.77 Billion ≈ $235.68 Million |
+6.98% |
| 2014-12-31 | ₩325.08 Billion ≈ $220.30 Million |
+90.38% |
| 2013-12-31 | ₩170.76 Billion ≈ $115.72 Million |
+86.62% |
| 2012-12-31 | ₩91.50 Billion ≈ $62.01 Million |
+169.83% |
| 2011-12-31 | ₩33.91 Billion ≈ $22.98 Million |
-92.02% |
| 2010-12-31 | ₩424.95 Billion ≈ $287.98 Million |
-5.69% |
| 2009-12-31 | ₩450.57 Billion ≈ $305.34 Million |
+1.15% |
| 2008-12-31 | ₩445.43 Billion ≈ $301.86 Million |
+31.25% |
| 2007-12-31 | ₩339.39 Billion ≈ $230.00 Million |
+44.80% |
| 2006-12-31 | ₩234.39 Billion ≈ $158.84 Million |
+23.83% |
| 2005-12-31 | ₩189.29 Billion ≈ $128.28 Million |
+3.40% |
| 2004-12-31 | ₩183.07 Billion ≈ $124.06 Million |
+6.31% |
| 2003-12-31 | ₩172.20 Billion ≈ $116.70 Million |
+8.25% |
| 2002-12-31 | ₩159.07 Billion ≈ $107.80 Million |
-3.08% |
| 2001-12-31 | ₩164.13 Billion ≈ $111.23 Million |
+5.05% |
| 2000-12-31 | ₩156.24 Billion ≈ $105.88 Million |
-- |
About Hanmi Science
Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer, as well as children's and adult's bowel preparation and cold medicines, and cephalosporin antibiotics. The company also offers general foods, health functional foods, soy milk, and medical equipment. In addition… Read more